Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 254 of 6351
-
Triple-drug attack aims to stop melanoma from coming back
Disease control OngoingNeoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).
Phase 2 • Sponsor: Fondazione Melanoma Onlus • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can stomach cancer surgery also tame diabetes?
Disease control Recruiting nowThis is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.
Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a single freeze procedure tame stubborn atrial fibrillation?
Disease control OngoingThis study aimed to evaluate the efficacy of Cryoablation in patients with early persistent atrial fibrillation as a first index procedure using continuous cardiac rhythm monitoring.
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Boosting thyroid cancer therapy: does rhTSH make radioactive iodine more effective?
Disease control CompletedThis is a randomized, open, parallel controlled, multi-center clinical trial; 120 subjects were randomly assigned to the test group and the control group according to 3:1.
Phase 2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New gene therapy trial hopes to restore muscle protein in duchenne boys
Disease control Recruiting nowCohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed. This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug shows promise for Hard-to-Treat breast cancer
Disease control OngoingThe goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens.
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy aims to fight metastatic anal cancer
Disease control OngoingThis phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New brain bleed surgery could save lives and reduce disability
Disease control Recruiting nowA randomized controlled trial of ultra-early, minimally invasive, hematoma evacuation versus standard care within 8 hours of intracerebral hemorrhage. Patients presenting to the emergency department with stroke due to supratentorial, spontaneous intracerebral hemorrhage \>20mL vo…
Sponsor: University of Melbourne • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New heart valve fix offers hope for those too sick for surgery
Disease control Recruiting nowThis study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollmen…
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New PET tracer could reveal hidden breast cancer throughout the body
Diagnosis Recruiting nowEstrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment. Pathological evaluations of primary tumor, axillary nodes, and metastases are the only c…
Phase 2 • Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Can a mechanical heart pump offer a lifeline for advanced heart failure?
Disease control CompletedThe Korea HM3 PMS is a prospective, single arm, open-label, multi-center, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure. The PMS will enroll up to 300 patients, that meet the Health In…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Clot-Buster shows promise for eye stroke in landmark trial
Disease control CompletedTENecteplase in Central Retinal Artery Occlusion (TenCRAOS): A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization). A Prospective, randomized-controlled, dou…
Phase 3 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can a triple attack shrink untreatable liver tumors?
Disease control CompletedThis study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
Phase 1 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New combo therapy aims to fight tough esophageal cancer
Disease control OngoingThis is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
A 20-Year-Old immune regulator faces its biggest test against HPV
Disease control Recruiting nowHuman papillomavirus (HPV) is a prevalent pathogen, the epidemiology of which has mostly been studied in the uterine cervix and the vagina. In Belgium, since 2025, HPV testing has become the primary screening method for cervical cancer. For women between 30 and 64 years, a clini…
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a tiny implant replace daily blood thinners for AFib patients?
Disease control OngoingThe primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a personalized drug strategy wipe out hidden myeloma cells?
Disease control OngoingThis phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving mi…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for myeloma: targeted drug combo shows promise in Late-Stage trial
Disease control OngoingThis study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (R…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a targeted antibody calm the immune attack in Huntington's disease?
Disease control CompletedThis study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with, or at risk for, manifest Huntington's Disease (HD).
Phase 2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo shows promise in halting esophageal cancer progression
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progre…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC